We analyzed 1,900 Turkish Behçet's disease cases and 1,779 controls genotyped with the Immunochip. The most significantly associated SNP was rs1050502, a tag SNP for HLA-B*51. In the Turkish discovery set, we identified three new risk loci, IL1A-IL1B, IRF8, and CEBPB-PTPN1, with genomewide significance (P < 5 × 10 −8 ) by direct genotyping and ADO-EGR2 by imputation. We replicated the ADO-EGR2, IRF8, and CEBPB-PTPN1 loci by genotyping 969 Iranian cases and 826 controls. Imputed data in 608 Japanese cases and 737 controls further replicated ADO-EGR2 and IRF8, and metaanalysis additionally identified RIPK2 and LACC1. The diseaseassociated allele of rs4402765, the lead marker at IL1A-IL1B, was associated with both decreased IL-1α and increased IL-1b production. ABO non-secretor genotypes for two ancestryspecific FUT2 SNPs showed strong disease association (P = 5.89 × 10 −15 ). Our findings extend the list of susceptibility genes shared with Crohn's disease and leprosy and implicate mucosal factors and the innate immune response to microbial exposure in Behçet's disease susceptibility.
Behçet's disease is a systemic vasculitis that manifests with oral ulcers, uveitis, skin inflammation, genital ulcers, and inflammation in other organs 1, 2 . Behçet's disease is relatively common in modern-day countries located along the ancient Silk Route 3 . The geographical distribution of Behçet's disease and lack of consistency with expected patterns of Mendelian inheritance, despite a high sibling risk ratio (λ s = 11.4-52.5) (ref. 4) , suggest that multiple genetic and environmental factors contribute to disease susceptibility. Although genetic studies have identified multiple susceptibility loci [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] , these genetic factors do not fully explain the apparent disease heritability.
To further clarify the genetic etiology of Behçet's disease, we genotyped 2,014 Turkish cases and 1,826 population controls using the Immunochip 15 . After quality control filtering, 130,647 autosomal markers genotyped in 1,900 cases and 1,799 controls were subjected to association tests. Association analysis showed the strongest disease association within the major histocompatibility complex (MHC) region ( Fig. 1) . Consistent with our previous findings using genomewide association study (GWAS) genotype data 16 , imputation of the MHC region and classical human leukocyte antigens (HLAs) showed the strongest association for HLA-B*51 (P = 5.67 × 10 −90 ; Table 1 and Supplementary Fig. 1 ) among all markers. Other HLA alleles also showed significant association with Behçet's disease ( Supplementary  Table 1 ), and regression analysis among MHC class I and II molecules confirmed independent disease-protective association for HLA-A*03 and disease susceptibility association for HLA-B*15 ( Supplementary  Table 2 ). Association analysis for SNPs showed the strongest disease association at rs1050502 (P = 9.99 × 10 −90 ; Table 1 ), a synonymous Dense genotyping of immune-related loci implicates host responses to microbial exposure in Behçet's disease susceptibility variant for isoleucine at position 47 of the HLA-B molecule and a tag SNP for HLA-B*51 (r 2 = 1).
In a previous Immunochip study of Behçet's disease, Hughes et al. 17 reported that rs116799036, a SNP in the HLA-B-MICA intergenic region, was more strongly associated with disease than HLA-B*51 and also reported three additional independent disease susceptibility markers in the MHC region, rs12525170, rs114854070, and HLA-Cw*16:02. In our study, the association P value for rs116799036 was 1.3 × 10 5 -fold higher (less significant) than the P value for HLA-B*51, and regression analysis identified significant residual association of HLA-B*51 after conditioning on each of the other markers ( Table 1) . In contrast, the associations of the other markers were completely abrogated by conditioning on HLA-B*51 ( Table 1 and Supplementary Fig. 1) , and the associations of these markers were strongly correlated with their linkage disequilibrium (LD) with HLA-B*51 (Supplementary Fig. 2) .
Outside of the MHC region, three new loci, IL1A-IL1B (rs3783550, P value corrected for genomic inflation (P GC ) = 2.12 × 10 −8 ), IRF8 (rs11117433, P GC = 2.73 × 10 −8 ), and CEBPB-PTPN1 (rs913678, P GC = 1.96 × 10 −9 ), and three previously reported loci, IL10, CCR1, and IL12A, displayed genome-wide significant associations with Behçet's disease based on Immunochip genotyping ( Fig. 1, Table 2 , and Supplementary Fig. 3 ). We also replicated the disease association of markers in other loci previously reported for Behçet's disease (IL23R-IL12RB2, ERAP1, KLRC4, and FUT2) but did not find evidence supporting an association for TNFAIP3 reported in a Han Chinese population 10 or JRKL-CNTN5 recently reported in a Spanish population 14 ( Supplementary Table 3 ).
Four significantly associated loci (IL1A-IL1B, IL12A, IRF8, and CEBPB-PTPN1) were not identified by our previous GWAS. Two of these loci (IL12A and IRF8) had no markers on the GWAS array in strong LD with the Immunochip lead SNP, and the associations were thus driven by the increased coverage on the Immunochip. The greater power provided by the larger sample size here also contributed to identifying disease associations at all four loci ( Supplementary Table 4 ).
For 12 of the 20 new loci with association P < 5 × 10 −5 ( Table 2 and Supplementary Table 5 ), imputation identified a more significant association, including rs4402765 in the IL1A-IL1B locus (P GC = 3.85 × 10 −9 ) and a genome-wide significant association at rs7075773 in the ADO-EGR2 locus (P GC = 2.96 × 10 −9 ; Supplementary Fig. 3 and Supplementary Table 6 ). Conditional regression analysis of the regions that exceeded genome-wide significance identified an independent contribution to disease susceptibility at rs7203487 in the IRF8 locus after conditioning on the lead SNP, rs11117433 (Supplementary Table 7 ).
For replication, the 21 lead SNPs genotyped by the Immunochip in the 20 new loci with association P < 5 × 10 −5 in the Turkish population were genotyped in the Iranian population comprising 969 cases and 826 controls. Four of these loci (ADO-EGR2, LACC1, IRF8, and CEBPB-PTPN1) replicated in the Iranian population ( Supplementary  Table 8 ). In a meta-analysis of the Turkish and Iranian populations, ADO-EGR2, IRF8, and CEBPB-PTPN1 exceeded genome-wide significance ( Table 3) .
We also evaluated the newly associated markers in the Japanese population, where possible, using imputed data from the previous Japanese GWAS in 608 cases and 737 controls, and we replicated association of rs9316059 in LACC1 ( Supplementary Table 9 ), which also exceeded genome-wide significance in a meta-analysis with Turkish data ( Supplementary Table 10 ). Furthermore, disease association of rs2121033 in the LACC1 locus, which is in strong LD with rs9316059 (r 2 = 0.99), was observed in all three populations, and a combined a The residual P value after conditioning on each marker determined using imputed data from 3,535 samples from Turkey with no missing genotype data for the six markers included in the regression analysis (1,840 cases, 1,735 controls). P < 1 × 10 −5 was considered to indicate independent association in the conditional regression analysis. b Present or absent. c Reported in Hughes et al. 17 .
l e t t e r s l e t t e r s meta-analysis found highly significant association for this marker (P GC = 3.54 × 10 −11 ; Table 3 ).
With imputed data available from both the Turkish and Japanese populations, we were able to perform a more comprehensive analysis of the new suggestive regions, allowing identification of associations with alternate markers other than the lead ones identified in the Turkish discovery collection. Meta-analysis of all markers with suggestive evidence of association (P < 5 × 10 −5 ) in the Turkish population that were also available in the Japanese data set identified four loci with genome-wide significant association, including the rs2121033 marker in the LACC1 locus described above. New markers in moderate LD with the Immunochip lead marker were identified in ADO-EGR2 and IRF8 ( Table 3 and Supplementary Table 11 ), and conditional analysis on the Turkish genotypes suggested that these new markers Chr., chromosome; A1, minor allele; A2, major allele; OR, odds ratio; CI, confidence interval. a rs17753641 in IL12A is in moderate LD with the SNP (rs17810546) previously reported in a multi-ancestry study 13 (r 2 = 0.77, D′ = 0.99). 11 . c Genotyping of rs9316059 in the LACC1 locus failed by TOF MS (time-of-flight mass spectrometry) in the Iranian population; therefore, rs2121033, the lead SNP for LACC1 after imputation, was genotyped instead (r 2 = 0.99 in Turkish). d rs7203487 showed independent disease association in conditional regression analysis for the lead SNP in the IRF8 locus, rs11117433. e Genotyping of rs142105922 in the IRF8 locus failed by TOF MS. rs1401884 in high LD with rs142105922 was genotyped instead (r 2 = 0.84).
l e t t e r s were not independent of the lead SNPs ( Supplementary Table 12 ).
The combined Turkish and Japanese meta-analysis also identified a new genome-wide significant association at rs2230801 (P GC = 6.57 × 10 −9 ), a missense variant of RIPK2 (p.Ile259Thr) ( Table 3 and Supplementary Table 11 ). In the Iranian collection, genotypes for the four markers that achieved genome-wide significance in the Turkish and Japanese meta-analysis demonstrated at least nominal evidence of association (P < 0.05), except for the rs2230801 variant in RIPK2 (Supplementary Table 13) , for which the power to replicate was low (0.32). All the newly identified Behçet's disease susceptibility markers are located in putative functional regions and have predicted functional effects, either altering protein structure or the expression of nearby genes (Supplementary Table 14) .
Although replication of associations in the IL1A-IL1B region did not reach statistical significance in the Iranian or Japanese samples, there was a trend for association, with a higher frequency of the risk allele in cases (Supplementary Tables 8 and 9 ). An expression quantitative trait locus (eQTL) study showed that the lead SNP associated with Behçet's disease risk, rs4402765, was also the SNP most significantly associated with IL1A gene expression in lymphoblastoid cells and showed that the disease risk allele was associated with reduced gene expression ( Fig. 2a,b, Supplementary Fig. 3 , and Supplementary Table 14 ). Consistent with the effect of this marker on IL1A gene expression, we also found that the amount of IL-1α protein in culture supernatants from healthy donor peripheral blood mononuclear cells (PBMCs) stimulated with zymosan was reduced in homozygotes for the rs4402765 risk allele as compared to homozygotes for the protective allele (Fig. 2c) . Although the published eQTL study did not show significant association of rs4402765 genotype with IL1B gene expression, we found that the concentration of IL-1β protein was significantly higher in the cell culture supernatants of homozygotes for the risk allele than it was in supernatants from homozygotes for the protective allele ( Fig. 2d) .
IL-1α is highly expressed in the epidermis and has an important role in skin barrier functions against pathogens 18 . IL-1α is also required for effective host defense against disseminated candidiasis 19 . Our findings suggest that genetically encoded reductions in IL-1α expression may contribute to susceptibility to Behçet's disease by weakening host response to and defense against invading pathogens. Disease susceptibility may also be increased by the risk allele's effect on IL-1β production in response to microbial pathogens. IL-1β levels are elevated in individuals with Behçet's disease 20, 21 . Recently, blockade of IL-1 or IL-1β in patients with Behçet's disease has been reported to be effective 22, 23 . Our study raises the intriguing possibility that the decreased barrier function of IL-1α combines with the increased inflammatory response of IL-1β to increase Behçet's disease risk.
FUT2 was recently reported to confer Behçet's disease susceptibility in a meta-analysis of Iranian and Turkish GWAS data 12 . We have expanded this analysis to examine functionally relevant homozygous genotypes in a large sample size from three populations. FUT2 encodes α(1, 2)-fucosyltransferase, which synthesizes secreted H antigen-the precursor of the ABO histo-blood group antigensin body fluids and the intestinal mucosa 24 . The rs601338[A] allele (Turks and Iranians) and rs1047781[T] allele (Japanese) are ancestry-specific FUT2 non-secretor mutations (encoding p.Trp143Ter and p.Ile129Phe, respectively), for which homozygosity leads to an ABO non-secretor phenotype 24 . We found significant associations of rs601338 with disease in Turks (P = 6.51 × 10 −9 ) and in Iranians (P = 1.65 × 10 −5 ), and we also found significant association of rs1047781 with disease in Japanese (P = 6.50 × 10 −4 ; Supplementary Table 15 ). These non-secretor genotypes are also associated with Crohn's disease risk 25, 26 and with gut microbiome composition 27, 28 . The non-secretor phenotype has also been associated with increased predisposition or resistance to different infectious agents [29] [30] [31] . Meta-analysis of the two common FUT2 non-secretor genotypes in Turks, Iranians, and Japanese yielded highly significant association (P = 5.89 × 10 −15 ; Supplementary Table 15 ), providing evidence that ABO nonsecretion, particularly at mucosal surfaces, increases the risk for Behçet's disease and implicating the microbial-host interface in disease pathogenesis.
Our study has increased the number of susceptibility loci shared by Behçet's disease and inflammatory bowel disease (IBD), which have many clinical features in common, to 11, adding 4 loci (ADO-EGR2, LACC1, IRF8, and CEBPB-PTPN1), thus indicating substantial genetic similarity between Behçet's disease and IBD ( Supplementary  Tables 16 and 17) (refs. 25,32,33) . In addition, markers within the reported susceptibility loci for IBD demonstrated greater enrichment for associations with Behçet's disease than expected by chance ( Supplementary Fig. 4) . Comparing among subgroups of IBD, our new findings emphasize higher genetic similarity of Behçet's disease with Crohn's disease (ADO-EGR2, RIPK2, LACC1, and IRF8) than with ulcerative colitis (ADO-EGR2 and CEBPB-PTPN1) ( Supplementary Table 17 ) (refs. 25,33) .
We also identified substantial overlap in the susceptibility loci for Behçet's disease and leprosy caused by infection with Mycobacterium leprae, adding three (RIPK2, ADO-EGR2, and LACC1) of the now four shared loci (Supplementary Table 17) (refs. 34-36 ). The reported l e t t e r s susceptibility loci for leprosy also showed relative enrichment for associations with Behçet's disease (Supplementary Fig. 4) .
Interestingly, the minor allele of the LACC1 lead SNP, rs2121033, confers protection for Behçet's disease but is in high LD with a common coding variant, rs3764147 (p.Ile254Val; r 2 = 0.93), that increases risk for IBD and Crohn's disease ( Supplementary Table 17 ). Furthermore, a rare mutation altering a residue in the laccase domain of the LACC1 protein, p.Cys284Arg, cosegregates with Mendelian systemic juvenile idiopathic arthritis and Crohn's disease in consanguineous families 37, 38 . A recent study reported that the p.Ile254Val variant leads to impaired protein function, and Lacc1 −/− mice produce decreased IL-1β in response to lipopolysaccharide (LPS) treatment, consistent with a role for IL-1β in Behçet's disease pathogenesis 39 . The minor allele of rs913678 (C) in the CEBPB-PTPN1 locus also showed opposite directions of effect in Behçet's disease (risk) and IBD (protective) ( Supplementary Table 17 ). This allele is associated with decreased gene expression (Supplementary Table 14) , and Cebpb −/− mice show increased susceptibility to pathogens 40, 41 . These opposite effects suggest that different mechanisms involving these loci increase disease risk for Behçet's disease as compared with IBD.
A limitation of the Immunochip approach is that only selected genetic regions were explored in this study. In addition, the Immunochip has a potential problem in genotype calling accuracy because it is a custom array. To avoid miscalling, we applied strict protocols for quality control and cluster file preparation in the Turkish population (Online Methods). The peak genotyped markers for each disease-associated locus in the Turkish population showed robust clustering (Supplementary Fig. 5) .
This Immunochip study with the largest discovery collection thus far and with two additional populations in the replication phase provides robust evidence that HLA-B*51 in the HLA-B locus is the primary genetic source of disease risk and identifies multiple new susceptibility loci for Behçet's disease. Genes in these loci contribute to the elucidation of disease pathogenesis by identifying disease-associated pathways, including pathways involved in host defense, inflammation, and immune response ( Supplementary Table 18 ). Although a connection has not yet been proven, pathogenic infections have been proposed as an important environmental factor contributing to both the development and exacerbation of Behçet's disease 42 . These pathways help to establish a link between genetic factors and environmental factors, such as microbial exposures, that together contribute to disease susceptibility. Our current findings implicate genetic determinants of mucosal barrier function and the host response to pathogens in Behçet's disease susceptibility and draw important parallels and distinctions with respect to other immune-related diseases. 
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Subjects. We studied 2,014 Behçet's disease cases and 1,826 genetically matched controls composed of the discovery and replication cohorts in previous GWAS and imputation studies 7, 9 . We also included 969 Iranian cases and 826 controls recruited in a previous study 12 and 608 Japanese cases and 737 controls recruited in a previous Japanese GWAS 8 for replication. All Turkish and Iranian individuals affected with Behçet's disease were diagnosed according to the International Study Group criteria for Behçet's disease 43 ( Supplementary  Table 19 ). All Japanese individuals affected with Behçet's disease were diagnosed according to the Japanese Behçet's disease criteria 44 ( Supplementary  Table 20 ). Characteristics of each population are shown in Supplementary  Table 21 . All study participants provided written informed consent, and the study was approved by the ethics committee of each investigative institution.
Behçet's disease susceptibility loci and overlap with other diseases. Susceptibility loci and lead SNPs that overlapped Behçet's disease susceptibility loci in other immune-related diseases and leprosy were extracted from ImmunoBase and the National Human Genome Research Institute (NHGRI) GWAS catalog. If the Behçet's disease lead SNP or a SNP in strong LD (r 2 > 0.8) was associated with the other disease, concordance of allelic effect was ascertained. In diseases with susceptibility loci with no disease-associated markers in strong LD with the Behçet's disease marker, concordant effects of diseaseassociated alleles were identified by eQTL effects, if available. LD data from the CEU population of the 1000 Genomes Project was applied. eQTL databases (Genevar 54,55 , Blood eQTL browser 56 , GTEx 57 , and summary data from 12 studies available in HaploReg v4) were used to extract gene expression data. Permutation tests were performed to evaluate the number of disease risk loci shared by Behçet's disease and IBD (Crohn's disease and ulcerative colitis) or leprosy by a random selection of 1,000,000 sets of the same number of susceptibility loci for each disease from the RefSeq gene list (22,345 genes). Associations with Behçet's disease in this study for markers located in susceptibility loci for IBD or leprosy from previous studies were plotted to evaluate whether they were enriched for associations with Behçet's disease.
Pathway analysis. The pathways in which susceptibility genes are involved were analyzed in the Gene Ontology (GO) database by DAVID (v6.7) (ref. 58 ). We used 21 susceptibility genes (including 9 newly associated genes) from this study in the pathway analysis. P values were corrected by Benjamini's method. P corrected < 0.05 was considered to be significant.
Data availability.
Statistical summary data for all markers genotyped with the Immunochip for which the discovery cohort showed genome-wide significant or suggestive association (P < 5 × 10 −5 ) are provided in a Supplementary Data Set.
